Bacteraemia isolates on 470 patients, with 556 associated bacteraemic or fungaemic episodes, receiving or not receiving OPAT
| OPAT | |||
|---|---|---|---|
| Yes (N=25) | No (N=531) | p Value* | |
| Escherichia coli, n (%) | 11 (44.0) | 192 (36.2) | 0.426 |
| ESBL +ve | 9 | 19 | <0.001† |
| ESBL −ve | 2 | 173 | |
| K. pneumonia, n (%) | 2 (8.0) | 51 (9.7) | 0.812 |
| ESBL +ve | 0 | 14 | 0.388† |
| ESBL −ve | 2 | 37 | |
| P. aeruginosa, n (%) | 0 | 24 (4.5) | 0.277 |
| MSSA, n (%) | 2 (8.0) | 51 (9.7) | 0.789 |
| MRSA, n (%) | 0 | 3 (0.6) | 0.706 |
| Candida species, n (%) | 1 (4.0) | 9 (1.7) | 0.397 |
| Other‡, n (%) | 9 (36.0) | 202 (38.0) | 0.837 |
One patient had a bacteraemic and non-bacteraemic episode, so this was recorded in both groups.
*Pearsons χ2 test. Tests each bacteraemic isolate verses all other bacteraemic isolate.
†ESBL +ve versus ESBL –ve for each bacteraemic isolate.
‡These include two S. paratyphi, one S. typhi, one P. mirabilis, one E. aerogenes, one Group G streptococcus, one Streptococcus viridans, one Acinetobacter and one Candida haemulonii.
ESBL, extended-spectrum β-lactamases; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; OPAT, outpatient parenteral antibiotic treatment.